Marchesini Displays CMP Pharma Inspection System at INTERPHEX
The Marchesini Group will introduce the CMP pharma inspection system to the US market at INTERPHEX 2019.
The Marchesini Group, which acquired CMP PHAR.MA in December, 2018, will introduce the CMP pharma inspection system to the US market at INTERPHEX 2019. CMP specializes in pharmaceutical inspection systems for ampules, vials, and syringes. SEA Vision, which is another partner in the Marchesini Group, co-participated in the CMP transaction, according to the Dec. 10, 2018 press release.
The CMP SA12J machine is an automatic inspection machine designed to perform visual inspection of prefilled syringes. This compact unit reaches a speed of up to 200 pieces per minute. It is also possible to combine it with a leak test unit to check containers' integrity.
The Group will also display the RE 202 rotary labeler developed by Neri, Marchesini’s division specializing in the production of labelling machines. The design of the RE 202 offers versatility in processing bottles made of a variety of materials (glass, plastic, and metal) and of different shapes (cylindrical, truncated cone, oval). The machine can process up to 200 containers per minute.
Also on display will be the Track Pack, a new, all-in-one solution for serialization, tamper-evident, and aggregation needs. The system combines the BL A415 labeller and the PS 300 case packer in a compact, automated machine.
Source: Marchesini Group
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
